Entero Therapeutics (NASDAQ:GRDX) Issues Earnings Results

Entero Therapeutics (NASDAQ:GRDX) announced its quarterly earnings results on Wednesday. The company reported ($0.82) EPS for the quarter, FiscalAI reports. The company had revenue of $0.04 million during the quarter.

Entero Therapeutics Stock Performance

Shares of Entero Therapeutics stock opened at $4.74 on Thursday. The company’s 50 day moving average price is $2.75. Entero Therapeutics has a 12 month low of $1.06 and a 12 month high of $5.84. The company has a market capitalization of $15.93 million, a price-to-earnings ratio of -2.80 and a beta of 1.38.

Hedge Funds Weigh In On Entero Therapeutics

An institutional investor recently bought a new position in Entero Therapeutics stock. DRW Securities LLC purchased a new stake in shares of Entero Therapeutics, Inc. (NASDAQ:GRDX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned about 1.45% of Entero Therapeutics at the end of the most recent quarter. 12.30% of the stock is owned by institutional investors.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.